How are human ivermectin doses determined for parasitic diseases and what are typical tablet strengths?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin dosing for humans is calculated chiefly on body weight and the target parasite, expressed in micrograms per kilogram (μg/kg); common therapeutic ranges are about 150–200 μg/kg for many nematode infections and higher regimens (e.g., 400 μg/kg) for some programs such as lymphatic filariasis (LF) control [1] [2]. The drug is usually given as a single oral dose that may be repeated at intervals for certain conditions, and commercially available human tablets are most commonly 3 mg (Stromectol), with other tablet sizes cited in the literature and international practice [3] [4] [5].
1. How dose is defined: the weight‑based, parasite‑specific rule
Clinical practice and systematic reviews emphasize that ivermectin dose is individualized by body weight and by the parasitic disease being treated, using micrograms per kilogram as the unit of measure—typical regimens for onchocerciasis, strongyloidiasis and enterobiasis fall in the 150–200 μg/kg range (0.15–0.2 mg/kg) [1] [2] [6]. Lymphatic filariasis and some programmatic uses may use higher per‑kilogram dosing (for example, 400 μg/kg in some settings), and mass drug administration (MDA) programs calculate community doses the same way to standardize efficacy and safety [1] [2]. These μg/kg targets come from clinical trials, long‑term field studies and WHO/academic recommendations and are intended to balance antiparasitic efficacy with the drug’s safety profile in humans [1] [2].
2. Single dose, repeats, and disease biology influence schedule
For many intestinal and filarial infections ivermectin is effective as a single oral dose, often taken fasting, but repeat doses are required for parasites with persistent adult stages or for recrudescence—onchocerciasis, for example, may require repeated dosing because ivermectin does not reliably kill adult Onchocerca worms [7] [8]. Scabies and crusted scabies regimens frequently call for multiple doses spaced days to weeks apart; strongyloidiasis commonly uses a single 0.2 mg/kg dose with follow‑up stool tests to confirm clearance [7] [8] [5]. Programmatic choices (single high dose vs repeated lower doses) reflect parasite life cycles, transmission dynamics and safety data from trials and community campaigns [2] [8].
3. Pharmacology and practical adjustments: food, liver, special populations
Ivermectin’s blood levels change with food: a high‑fat meal can markedly increase oral bioavailability, so dosing guidance often specifies taking tablets on an empty stomach unless a regimen dictates otherwise; the FDA label documents a roughly 2.5‑fold bioavailability increase after a standard high‑fat meal in pharmacokinetic studies [9]. The drug is extensively metabolized in the liver, so clinicians apply caution and consider adjustments or monitoring in liver disease or elderly patients with comorbidities, and children under certain weights are excluded from some human formulations until safety is established [8] [3].
4. Typical tablet strengths and practical dosing calculations
The FDA‑approved human tablet marketed as Stromectol is 3 mg per tablet and many drug information sources list 3 mg as the standard tablet strength used to calculate weight‑based doses [3] [10]. Other references and international practice note 6 mg and 12 mg tablet sizes in circulation, and community programs may use different formulations or tablet counts to achieve the target μg/kg dose [5] [4]. For example, a 60 kg adult receiving 200 μg/kg would require 12 mg total (0.2 mg/kg × 60 kg = 12 mg), which is commonly achieved by administering four 3 mg tablets [3] [5].
5. Safety notes, off‑label use and limits of the reporting
Human dosing limits and safety margins are well documented from trials and decades of use, but high doses (and veterinary formulations) can be toxic; clinical labels and authorities warn against self‑medicating with animal ivermectin products and caution that ivermectin is not approved for COVID‑19 [9] [11] [6]. Sources vary slightly in recommended μg/kg ranges and in listed tablet sizes, reflecting differences across regulatory labels, clinical guidelines and international practice; where sources do not agree, this analysis reports the ranges and tablet strengths that recur in regulatory labels, systematic reviews and prescribing references [1] [3] [2].